The legal history of mifepristone in the United States of America. How medical abortion is (partially) filling in the gaps lacking protection after the Supreme Court’s overturn of Roe

Authors

  • Marianna Bergamaschi

DOI:

https://doi.org/10.15168/2284-4503-3468

Keywords:

Reproductive rights, medical abortion, mifepristone, Supreme Court, judicial review

Abstract

After the Dobbs landmark decision restored the power to regulate and ban abortion to individual states in 2022, the Supreme Court was called to address reproductive rights once again in 2024. In Food and Drugs Administration v. Alliance for Hippocratic Medicine, anti-abortion groups and some medical professionals demanded a declaration of illegitimacy for mifepristone, the drug used for medication abortions, along with the regulatory framework of the drug, established and updated through time by the Food and Drug Administration (FDA). Although the Justices recognized that the plaintiffs lacked standing without delving into the case’s merits, the importance of scientific evaluations in judicial reasoning is an increasingly relevant matter.

Published

2025-05-08

How to Cite

1.
Bergamaschi M. The legal history of mifepristone in the United States of America. How medical abortion is (partially) filling in the gaps lacking protection after the Supreme Court’s overturn of Roe. BioLaw [Internet]. 2025 May 8 [cited 2025 Jun. 25];(1):115-29. Available from: https://teseo.unitn.it/biolaw/article/view/3468

Issue

Section

Call for papers